Clinical trials: Methylphenidate Abuse
Attention Deficit Hyperactivity Disorder
Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)
Previous studies using transcranial magnetic stimulation (TMS) with paired pulse protocols have shown that a conditioning TMS pulse applied to the human motor cortex changes the excitability of motor pathways from the motor…
- Trial name
- ADHD (NCT01651169)
- Testing
- methylphenidate tablets and Inter-stimulus Intervals (ISI)
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Tehran University of Medical Sciences
Naltrexone, Methylphenidate Abuse
Study for Naltrexone on the Abuse Potential of Methylphenidate
The current abuse liability study aims to assess the potential for co-administration of naltrexone (NTX) to reduce the abuse potential of methylphenidate (MPH).
- Trial name
- NCT03769064
- Testing
- Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Avekshan LLC
Attention Deficit Hyperactivity Disorder (ADHD)
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Abuse of psychoactive substances is a behavior belonging to the field of risk behaviors that begins and takes place during adolescence. These risk behaviors are a major public health problem in France and worldwide.
- Trial name
- METHACAN (NCT03481959)
- Testing
- Methylphenidate
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ADHD, Cannabis Use Disorder
Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder
The goal of this clinical trial is to look at how delayed-release, extended-release methylphenidate (Jornay PM), an FDA-approved medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), works to treat ADHD…
- Trial name
- NCT07838311
- Testing
- Delayed-release, extended-release methylphenidate
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Massachusetts General Hospital
Drug Abuse
The Effects of Expectation on Natural and Drug -Induced Rewards
Background: Environmental cues frequently induce expectancies in individuals that may strongly influence the actual experience associated with the cue.
- Trial name
- NCT01036230
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Attention Deficit Disorder With Hyperactivity
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with…
- Trial name
- NCT04132557
- Testing
- Methylphenidate, Lisdexamfetamine, Atomoxetine
- Where
- United States
- Volunteers
- 430,000 people
- Sponsor
- Janssen Research & Development, LLC
ADHD, Attention Deficit Hyperactivity Disorder
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
The study team will examine the effects of FDA approved stimulant and non-stimulant medications for ADHD, among youth with ADHD and with and without Oppositional Defiant Disorder (ODD) or Conduct Disorder (CD), on reward systems…
- Trial name
- MPH-ATX (NCT03781765)
- Testing
- Methylphenidate, Atomoxetine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
ADHD, Substance Abuse
Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.
- Trial name
- NCT00264797
- Testing
- Methylphenidate (OROS-MPH)
- Where
- 12 sites in United States
- Volunteers
- 303 people
- Sponsor
- University of Cincinnati
Psychoactive Substances Consumption, Substance-related Disorder
French Study on COgnitive Enhancement and Consumption of Psychoactive Substances Among Youth Students
This descriptive and declarative study will help to find out consumption rates, all psychoactive substances taken together, among 18-25 year olds.
- Conditions
- Psychoactive Substances Consumption, Substance-related Disorder, Off Label-use, Cognitive Enhancement
- Trial name
- ENQUETE-COSYS (NCT02954679)
- Testing
- Online self-administrated and anonymous survey questionnaire
- Where
- France
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
Methylphenidate Treatment for Cocaine Abuse and ADHD - 1
Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD.
- Trial name
- NCT00136734
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- New York State Psychiatric Institute
Methamphetamine Dependence, Methamphetamine Abuse
Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)
This is a human inpatient clinical pharmacology study to assess potential interactions between intravenous (i.v.) methamphetamine infusion and oral osmotic release methylphenidate (OROS-MPH).
- Trial name
- NCT00603434
- Testing
- OROS-MPH
- Where
- 2 sites in United States, Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Substance Abuse
Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics
Background: Research has shown that several human genes have been associated with vulnerability to substance abuse and dependence.
- Trial name
- NCT00247689
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cocaine Addiction, Cocaine Abuse
Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates
Background: Brain imaging studies, genetic research, and investigations of stress have provided more information about the role of dopamine in processing reward and punishment, and in vulnerability to substance dependence.
- Trial name
- NCT00865332
- Where
- 2 sites in United States
- Sponsor
- National Institute on Drug Abuse (NIDA)